medigraphic.com
ISSN 0185-3325 (Impreso)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2001, Número 4

<< Anterior

Salud Mental 2001; 24 (4)


Vegetal marijuana, animal marijuana

Prospéro GO, Murillo-Rodríguez E, Martínez GD, Méndez DM, Velázquez MJ, Navarro L

Idioma: Español
Referencias bibliográficas: 55
Paginas: 58-64
Archivo PDF: 195.78 Kb.


RESUMEN

La mariguana es uno de los productos ilícitos de abuso que más se usa en el mundo. Los mecanismos por los cuales afecta al cerebro se han estudiado exhaustivamente en los últimos 40 años, pero se han entendido mejor en la última década. Por ejemplo, conocer los receptores a los que se une la mariguana ha sido un gran descubrimiento en el área de las neurociencias. Asimismo, la descripción de ligandos endógenos, los endocanabinoides, ha arrojado luz para entender la fisiología cerebral que regula desde el dolor hasta el placer y desde el sexo hasta el pensamiento. Por todos estos efectos, los endocanabinoides son un tema de estudio con fines terapéuticos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. ADAMS IB, RYAN W, SINGER M, THOMAS BF,COMPTON DR, RAZDAN RK, MARTIN BR: Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J Pharmacol Exp Ther, 273:1172-1181, 1995.

  2. AMERI A: The effects of cannabinoids on the brain. Prog Neurobiol, 58: 315-348, 1999.

  3. BELTRAMO M, DE FONSECA F R, NAVARRO M, CALIGNANO A, GORRITI MA, GRAMMATIKOPOULOS G, SADILE AG, GIUFFRIDA A, PIOMELLI D: Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J Neurosci, 20:3401-3407, 2000.

  4. BORING DL, BERGLUND BA, HOWETT AC: Cerebrodiene, arachidonyl-ethanolamide, and hybrid structures: potential for interaction with brain cannabinoid receptors. Prostaglandins Leukot, Essent Fatty Acids, 55:207-210, 1996.

  5. CRAVATT DF, PROSPERO-GARCIA O, SIUZDAK G, GILULA NB, HENRIKSEN SJ, BORGEN DL, LERNER RA: Chemical characterization of a family of brain lipids that induce sleep. Science, 268:1506-1509, 1995.

  6. CRAVATT BF, GIANG DK, MAYFIELD SP, BOGER DL, LERNER RA, GILULA NB: Molecular characterization of an enzime that degrades neuromodulatory fatty-acid amides. Nature, 384:83-87, 1996.

  7. CHILDERS SR, DEADWYLER SA: Role of cyclic AMP in the actions of cannabinoid receptors. Biochem Pharmacol, 52:819-827, 1996.

  8. COMING DE, BLUM K: Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog Brain Res, 126:325-341, 2000.

  9. DESMAUD F, CADAS H, PIOMELLI D: Anandamide amidohydrolase activity in rat brain microsomes. J Biol Chem, 270:6030-6035, 1995.

  10. DEVANE WA, HANUS L, BREUER A, PERTWEE RG, STEVENSON LA, GRIFFIN G, GIBSON D, MANDELBAUM A, ETINGER A, MECHOULAM R: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258:1945-1949, 1992.

  11. DI MARZO V, BISONO T, DE PETROCELLIS L, MELCK D, MARTIN BR: Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids. Curr Med Chem, 6:721-744, 1999.

  12. EDGAR PF, DOUGLAS JE, COOPER GJS, DEAN B, KYDD D, FAULL R LM: Comparative proteome analysis of hippocampus implicates chromosome 6q in schizophrenia. Mol Psychiat, 5:85-90, 2000.

  13. FAN P: Cannabinoid agonists inhibit the activation of 5- HT3 receptors in rat nodose ganglion neurons. J Neurophysiol, 73:907-910, 1995.

  14. FERRARI F, OTTANI A, GIULIANI D: Inhibitory effects of the cannabinoid agonist HU 210 on rat sexual behavior. Physiol Behav 69:547-554, 2000.

  15. FELDER CC, JOYCE KE, BRILEY EM, MANSOURI J, MAKIE K, BLOND O, LA Y, MA AL, MITCHELL RL: Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptor. Mol Pharmacol, 48:443-450, 1995.

  16. FELDER CC, GLASS M: Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol, 38:179-200, 1998.

  17. FREEDLAND CS, POSTON JS, PORRINO LJ: Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacol Biochem Behav, 67: 265-270, 2000.

  18. FRIDE E, MECHULAM R: Pharmacological activity of the cannabinoid receptor agonist, anadamide, a brain constituent. Eur J Pharmacol, 231:313-314, 1993.

  19. GERARD CM, MOLLEREAU C, VASSART G, PARMENTIER M: Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J, 279:129-134, 1991.

  20. GIUFFRIDA A, PARONS LH, KERR TM, RODRIGUEZ DE FONSECA F, NAVARRO M, PIOMELLI D: Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci, 2:358-363, 1999.

  21. GRINSPOON L, BKALAR JB: Marihuana the Forbidden Medicine. Yale University Press, New Haven, 1997.

  22. HAO S, AVRAHAM Y, MECHOULAM R, BERRY EM: Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in dietrestricted mice. Eur J Pharmacol, 392:147-156, 2000.

  23. HAYAISHI O: Molecular mechanisms of sleep-wake regulation: roles of prostaglandins D2 and E2. FASEB J, 5:2575-2581, 1991.

  24. HERKENHAM M, LYNN AB, JOHNSON MR, MELVIN LS, DE COSTA BR et al: Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradographic study. J Neurosci, 11:563-583, 1991.

  25. HERKERHAM M, LYNN AB, LITTLE MD, JOHNSON MR, MELVIN LS et al: Cannabinoid receptor localization in brain. Proc Natl Acad Sc USA, 87:1932-1936, 1990.

  26. HOWLETT AC: Pharmacology of cannabinoid receptors. Ann Rev Pharmacol Toxicol, 35:607-634,1995.

  27. HOWLETT AC, MUKHOPADHYAY S: Cellular signal transduction by anandamide and 2-arachidonylglycerol. Chem Phys Lipids, 108:53-70, 2000.

  28. HOEHE MR, CAENAZZO L, MARTINEZ MM, HSIEH WT, MODI WS, GERSHON ES, BONNER TL: Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14-q15. New Biologist, 3:880-885, 1991.

  29. HUIDOBRO-TORO JP, HARRIS RA: Brain lipids that induce sleep are novel modulators of 5-hydroxytryptamine receptors. Proc Natl Acad Sc USA, 93:8078-8082, 1996.

  30. KOOB FG: Neural mediation of addictive behavior. In: Handbook of Behavioral State Control. Cellular and Molecular Mechanisms. Lydic R, Baghdoyan HA (eds.). CRC Press, pp 365-389, Washington, 1999.

  31. LANGSTEIN J, HOFSTADTER F, SCHWARZ H: Cis- 9, 10-octadecenoamide, an endogenous sleep-inducing CNS compound, inhibits lymphocyte proliferation. Res Immunol,147: 389-396, 1996.

  32. LEDENT C, VALVERDE O, COSSU G, PETITE F, AUBERT JF, BESLOT F, BOHME GA, IMPERATO A, PEDRAZZINI T, ROQUES BP, VASSART G, FRATTA W, PARMENTIER M: Unresponsiveness to cannabinoids and reduced addictive effects of opiate in CB1 receptor knockout mice. Science,283:401-404, 1999.

  33. LEPORE M, VOREL SR, LOWINSON J, GARDNER EL: Conditioned place preference induced by delta 9- tetrahydrocannabinol: comparison with cocaine, morphine and food reward. Life Sci, 56:2073-2080, 1995.

  34. LERNER RA, SIUZDAK G, PROSPERO-GARCIA O, HENRIKSEN SJ, BOGER DL, CRAVATT BF: Cerebrodiene: a brain lipid isolated from sleep-deprived cats. Proc Natl Acad Sci USA, 91:9505-9508, 1994.

  35. LICHTMAN AH, DIMEN KR, MARTIN BK: Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacol, 119:289-290,1995.

  36. MANZONI OJ, BOCKAERT J: Cannabinoids inhibit GABAergic synaptic transmission in mice nucleus accumbens. Eur J Pharmacol, 412:R3-R5, 2001.

  37. MOLINA-HOLGADO V, GONZALEZ MI, LERET MC: Effect of delta 9-tetrahydrocannabinol on short-term memory in the rat. Physiol Behav, 57:172-179, 1995.

  38. MUNRO S, THOMAS KL, ABU-SHAAR M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65, 1993.

  39. MURILLO-RODRIGUEZ E, SANCHEZ-ALVAREZ M, NAVARRO L, MARTINEZ-GONZALEZ D, DRUCKER-COLIN R, PROSPERO-GARCIA O: Anandamide modulates sleep and memory in rats. Brain Res, 812:270-274, 1998.

  40. MURPHY LL, GHER J, STEGER RW, BARTKE A: Effects of Δ9-tetrahydrocannabinol on copulatory behavior and neuronedocrine responses of male rats to female conspecifics. Pharmacol Biochem Behav, 48:1011-1017, 1994.

  41. MUSTY RE, REGGIO P, CONSROE P: A review of recent advances in cannabinoid research and the 1994 International Symposium on Cannabis and the Cannabinoids. Life Sci, 56:1933-1944, 1995.

  42. PARKER LA, GILLIES T: THC-induced place and taste aversions in Lewis and Sprangue-Dawley rats. Behav Neurosci, 109:71-78, 1995.

  43. PERTWEE RG, STEVENSON LA, GRIFFIN G: Crosstolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. Br J Pharmacol, 110:1483-1490, 1993.

  44. PIOMELLI D: The ligand that came from within. TIPS, 22:17-19, 2001.

  45. PIOMELLI D, GIUFFRIDA A, CALIGNANO A, RODRIGUEZ DE FONSECA F: The endocannabinoid system as a target for therapeutic drugs. TIPS, 21:218-224, 2000.

  46. PROSPERO-GARCIA O, CRAVATT BE, SIUZDAK G,BOGER DL, LERNER RA, HENRIKSEN SJ: CIS-9, 10 Octadecenoamide: a novel natural lipid isolated from cat CSF with potential sleep-modulating properties. Sleep Res, 24:50, 1995.

  47. PROSPERO-GARCIA O, MURILLO-RODRIGUEZ E, JIMENEZ-ANGUIANO A, NAVARRO L, SANCHEZ M, GOMEZ M, MARTINEZ-GONZALEZ D, PALOMERO M, DRICKER-COLIN R: Psychomimetic drugs, marijuana and 5-HT antagonists. In: Handbook of Behavioral State Control. Cellular and Molecular Mechanisms. Lydic R, Baghdoyan H A (eds.). CRC Press, pp 433-442, Washington, 1999.

  48. RAY O, KSIR C: Drugs, Society, and Human Behavior. (Seventh edition), Mosby, Chap. 16 and 17. Boston, 1996.

  49. SIEGLING A, HOFMAN HA, DENZER D, MAULER F, DE VRY J: Cannabinoid CB1 receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol, 415:R5-R7, 2001.

  50. SMITH PB, COMPTON DR, WELCH SP, RAZDAN RK, MECHOULAM R, MARTIN BR: The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Ther, 270:219-227, 1994.

  51. TERRANOVE JP, STORME JJ, LAFON N, PERIO A, RINALDI-CARMONA M, LE FUR G, SOUBRIE P: Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR141716. Psychopharmacology, 126:165-172, 1996.

  52. WARTMAN M, CAMPBELL D, SUBRAMANIAN A,BURSTEIN SH, DAVIS RJ: The MAP-Kinase signal transduction pathway is activated by endogenous cannabinoid anandamide. FEBS Let, 359C:133-136, 1995.

  53. WELCH SP, DUNLOW LD, PATRICK GS, RAZDAN RK: Characterization of anandamide- and fluoroanandamideinduced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9- THC-induced antinociception. J Pharmacol Exp Ther, 273:1235-1244, 1995.

  54. WILEY J, BALSTER R, MARTIN B: Discriminative stimulus of anandamide in rats. Eur J Phamacol, 276:49-54, 1995.

  55. WILLIAMS CM, KIRKHAM TC: Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacol, 143:315-317, 1999.




2020     |     www.medigraphic.com